Thrombosis rate is higher with bioresorbable scaffolds than metallic stents, study findsBMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j1640 (Published 31 March 2017) Cite this as: BMJ 2017;356:j1640
- Susan Mayor
Patients with coronary artery disease who undergo routine percutaneous coronary intervention (PCI) showed similar rates of target vessel failure but higher incidence of device thrombosis when a bioresorbable vascular scaffold was used instead of a metallic stent, in preliminary results from a randomised trial.1
Drug eluting metallic stents are the standard of care for PCI, but their rigid structure can affect blood flow and lead to atherosclerosis and stent thrombosis. Bioresorbable stents were developed to remove the presence of a permanent implant and to allow normal blood vessel function. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial